Skip to main content

Table 2 Patient characteristics

From: Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)

  Pre-progression(N = 7332) Post-progression(N = 5062) Total(N = 8862)
Gender
 Men 3894 (53.1%) 2829 (55.9%) 4764 (53.8%)
 Women 3438 (46.9%) 2233 (44.1%) 4098 (46.2%)
Age (years)
 Mean ± SD 63.4 ± 15.9 64.2 ± 15.7 63.7 ± 15.9
 Median (Min. – Max.) 65 (18–103) 66 (18–99) 65 (18–103)
Initial progression marker
 Cerebral metastasesa   1348 (26.6%)  
 New metastases in other sites   2027 (40.0%)  
 Palliative care   1058 (20.9%)  
  With cerebral metastases   300 (5.9%)  
  Without cerebral metastases   758 (15.0%)  
 Treatment change   629 (12.4%)  
  1. aWithout delivery of palliative care